Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
November 27, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
November 25, 2024 07:30 ET
|
Medicenna Therapeutics Corp.
MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing...
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
November 15, 2024 07:30 ET
|
Medicenna Therapeutics Corp.
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
November 13, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC
November 11, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with...
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 08, 2024 10:00 ET
|
Medicenna Therapeutics Corp.
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 04, 2024 09:07 ET
|
Medicenna Therapeutics Corp.
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked,...
Medicenna Announces Results of Annual Meeting of Shareholders
September 26, 2024 17:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the...
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
September 09, 2024 07:32 ET
|
Medicenna Therapeutics Corp.
MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...